Editor's Note: TheStreet ratings do not represent the views of TheStreet's staff or its contributors. Ratings are established by computer based on metrics for performance (which includes growth, stock performance, efficiency and valuation) and risk (volatility and solvency). Companies with poor cash flow or high debt levels tend to earn lower ratings in our model All three major indices are trading up today with the Dow Jones Industrial Average ( ^DJI) trading up 153 points (1.0%) at 15,456 as of Tuesday, May 28, 2013, 12:50 PM ET. The NYSE advances/declines ratio sits at 2,106 issues advancing vs. 846 declining with 109 unchanged. The Drugs industry currently sits up 1.0% versus the S&P 500, which is up 0.9%. Top gainers within the industry include Valeant Pharmaceuticals International ( VRX), up 7.2%, Biogen Idec ( BIIB), up 2.5%, Celgene Corporation ( CELG), up 2.2%, Abbott Laboratories ( ABT), up 2.0% and AstraZeneca ( AZN), up 1.5%. TheStreet Ratings group would like to highlight 5 stocks pushing the industry higher today: 5. Amgen ( AMGN) is one of the companies pushing the Drugs industry higher today. As of noon trading, Amgen is up $0.58 (0.55) to $106.49 on light volume Thus far, 1.5 million shares of Amgen exchanged hands as compared to its average daily volume of 4.2 million shares. The stock has ranged in price between $106.39-$108.03 after having opened the day at $106.76 as compared to the previous trading day's close of $105.91. Amgen Inc., a biotechnology medicines company, engages in the discovery, development, manufacture, and marketing of human therapeutic products in the areas of supportive cancer care, inflammation, nephrology, and bone diseases primarily in the United States, Europe, and Canada. Amgen has a market cap of $79.4 billion and is part of the health care sector. The company has a P/E ratio of 17.9, above the S&P 500 P/E ratio of 17.7. Shares are up 22.9% year to date as of the close of trading on Friday. Currently there are 10 analysts that rate Amgen a buy, no analysts rate it a sell, and 13 rate it a hold. TheStreet Ratings rates Amgen as a buy. The company's strengths can be seen in multiple areas, such as its solid stock price performance, impressive record of earnings per share growth, compelling growth in net income, revenue growth and notable return on equity. We feel these strengths outweigh the fact that the company has had generally high debt management risk by most measures that we evaluated. Get the full Amgen Ratings Report now. Exclusive Offer: Jim Cramer's 'go-to' small/mid-cap guru Bryan Ashenberg only buys stocks he thinks could return 50-100%. See his top picks for 14-days FREE.